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Background: Neoadjuvant erlotinib and customized adjuvant therapy are appealing but controversial. The purpose
of this study was to evaluate the role of biomarker-guided neoadjuvant treatment strategy in patients with IIIA-N2
non-small cell lung cancer (NSCLC) stratified by epidermal growth factor receptor (EGFR) mutation status.
Findings: Patients with resectable histologically documented stage IIIA-N2 NSCLC were assigned to a neoadjuvant
erlotinib arm or a gemcitabine/carboplatin (GC) arm based on EGFR mutation status. The primary endpoint was
response rate (RR). Secondary endpoints were progression-free survival (PFS) and overall survival (OS).
Twenty-four patients with IIIA-N2 NSCLC were enrolled in the trial from January 2008 until May 2011. The overall
response rate was 41.7 % and the PFS and OS were 7.9 and 23.2 months, respectively, in overall population. The RR
was 58.3 % (7/12) for the erlotinib arm with mutant EGFR and 25.0 % (3/12) for the GC arm with wild type EGFR
(P = 0.18). Median PFS was 6.9 months versus 9.0 months, respectively (P = 0.071). Median OS was 14.5 months for
the erlotinib arm and 28.1 months for the GC arm (P = 0.201). No unexpected toxicities were observed.
Conclusions: The primary endpoint was met and biomarker-guided neoadjuvant treatment strategy in patients
with IIIA-N2 NSCLC is feasible. Erlotinib alone in neoadjuvant setting of EGFR mutant population showed an
improved response but without survival benefits.
Trial registration: ClinicalTrials.gov NCT00600587 https://www.clinicaltrials.gov/ct2/show/
NCT00600587?term=NCT00600587&rank=1
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Background
Patients with stage IIIA non-small cell lung cancer
(NSCLC) represent a relatively heterogeneity with ipsi-
lateral mediastinal lymph nodes (N2) involved, and
relative roles of treatment modalities are not clearly de-
fined. Chemoradiotherapy is an important treatment
for stage IIIA disease but limited by treatment-related* Correspondence: syylwu@live.cn
†Equal contributors
Guangdong Lung Cancer Institute, Guangdong General Hospital &
Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080,
People’s Republic of China
© 2015 Zhong et al.life-threatening toxicities [1]. And previous work
showed that status of gene expression was related to
different degrees of how much gemcitabine improved
survival of patients with advanced NSCLC [2]. Recently,
an individual participant data meta-analysis [3] found
that neoadjuvant chemotherapy improves an absolute
5-year survival of 5 % and may be preferable for pa-
tients with poorer prognosis or larger tumors. However,
chemotherapy has reached a therapeutic plateau in
NSCLC. A literature-based meta-analysis reported [4]
that tyrosine kinase inhibitors (TKIs) could provide
more survival benefits for patients with advanced epi-
dermal growth factor receptor (EGFR) mutant NSCLC,
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mutations when exploring efficacy of targeted therapy. In
patients with EGFR mutation positive NSCLC, an EGFR-
TKI may provide a dramatic response in a metastatic set-
ting [5–7]. The primary analysis in the OPTIMAL study,
comparing first-line erlotinib with gemcitabine/carbopla-
tin (GC) in patients with advanced NSCLC with EGFR
mutations, showed relatively higher response rate of
82.9 % (68/82) and significantly longer progression-free
survival (PFS) with erlotinib than with GC therapy [8].
Since 2007, several case reports and retrospective studies
with small sample sizes have shown that neoadjuvant
EGFR-TKI therapy results in N2 downstaging in patients
with stage IIIA-N2 NSCLC harboring EGFR mutation
[9–12]. In two phase II studies, neoadjuvant EGFR-TKI
showed low toxicity and sufficient activity in an enriched
population [13, 14]. However, no survival data in neoadju-
vant TKI therapy were obtained.
In the near future, lung cancer treatment will likely be-
come more patient-tailored by a molecular-based strategy.
Neoadjuvant EGFR-TKI therapy and customized adjuvant
therapy (IFCT-0801, TASTE trial) are appealing but con-
troversial strategies in patients with IIIA-N2 NSCLC [15].
The aim of this study was to investigate the efficacy ofTable 1 Baseline patient demographics and clinical characteristics
Characteristic Erlotinib
Median age at diagnosis (years) 60.17 ± 13.31
Gender, n (%)
Male 6 (6/12, 50.00 %)
Female 6 (6/12, 50.00 %)
Smoking duration 6.25 ± 11.89
Daily cigarette consumption, n 7.92 ± 14.99
Pathology, n (%)
Adeno 11 (11/12, 91.67 %)
LCNEC 0 (0.00 %)
Adenoid cystic carcinoma 1 (1/12, 8.33 %)
Mutation status, n (%)
EGFR/KRAS wild type 0
KRAS 0
Exon 19 deletion 6
L858R 4
EGFR mutation with KRAS codon 1
12/13*
EGFR mutation with EML4-ALK* 1
Deletion in BIM 2/8
Postoperative radiotherapy, n 3/6
Median follow-up (months) 19.3 (5.8–64.0)
EGFR epidermal growth factor receptor, LCNEC large-cell neuroendocrine carcinoma
*Two patients in the erlotinib arm with the EGFR L855R mutation also had the KRAbiomarker-guided neoadjuvant treatment strategy with er-
lotinib versus GC regimen in patients with stage IIIA-N2
NSCLC stratified by EGFR activating mutations and ex-
plore a new treatment strategy for this subset of patients.Results and discussion
Results
Patient characteristics
Twenty-four patients with IIIA-N2 NSCLC diagnosed by
mediastinoscopy or endobronchial ultrasound (EBUS)
were enrolled from January 2008 to May 2011. The cutoff
date for PFS and overall survival (OS) data was March
22nd, 2015. The median follow-up was 24.4 months
(range, 1.7–68.7 months). Twelve cases with a mutant-
type EGFR were assigned to the erlotinib arm and 12 cases
with wild type EGFR to the GC arm. In the erlotinib arm,
two patients with EGFR L858R mutation also had a KRAS
mutation or EML4-ALK translocation. No T790M muta-
tion was found in surgical specimens after neoadjuvant
erlotinib therapy. Age, gender, smoking status, histology,
postoperative radiotherapy, and the median follow-up
were balanced between arms. The clinical and histological
data for all patients are listed in Table 1.GC P value
58.75 ± 12.12 0.71
0.68
8 (8/12, 66.67 %)
4 (4/12, 33.33 %)
20.83 ± 21.09 0.10
17.92 ± 18.27 0.18
1.00
11 (11/12, 91.67 %)












, GC gemcitabine/carboplatin, BIM Bcl-2-interacting mediator of cell death
S mutation or EML4-ALK translocation
Table 2 Evaluation of neoadjuvant therapy efficacy
Index Evaluation Erlotinib arm n = 12, (%) GC arm n = 12, (%) P value
RECIST PR 7/12 (58.33) 3/12 (25.00) 0.18
SD 2/12 (16.67) 6/12 (50.00)
PD* 3/12 (25.00) 2/12 (16.67)
NA 0 (0.00) 1/12 (8.33)
Clinical N2 downstaging 3/12 (25.00) 3/12 (25.00) 1.00
Pathological N2 downstaging 2/12 (16.67) 3/12 (25.00) 0.64
Resection R0 3/6 (50.00) 5/7 (71.43) 0.59
R1 3/6 (50.00) 2/7 (28.57)
Values are presented as n (percentage)
GC gemcitabine/carboplatin, RECIST Response Evaluation Criteria in Solid Tumors, PR partial response, SD stable disease, PD progressive disease, NA not available
*Two patients with the EGFR L858R mutation and the KRAS mutation or EML4-ALK translocation developed primary resistance to induction erlotinib
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The overall response rate was 41.7 %(10/24). The RR
was 58.3 % (7/12) in the erlotinib arm and 25.0 % (3/12)
in the GC arm (P = 0.18). Overall, 54.2 % (13/24) pa-
tients received surgical resection. Three of six cases in
the erlotinib arm and five of seven cases in the GC arm
underwent complete resection (R0). The clinical N2
downstaging rate was 25.0 % (3/12) in both arms. The
pathological N2 complete response rates were 16.7 % (2/
12) versus 25 % (3/12) (P = 0.64) (Table 2 and Fig. 1).Fig. 1 Waterfall plot of response to neoadjuvant treatment. Abbreviations:
one case in the GC arm was not availableSurvival and failure models [16]
Overall, the PFS and OS were 7.9 and 23.2 months, re-
spectively (Fig. 2a). The median PFS was 6.9 months
(95 % confidence interval (CI), 3.8–10.0) for erlotinib
arm and 9.0 months (95 % CI, 3.1–15.0) for GC arm
(P = 0.071). The median OS was 14.5 months (95 % CI,
1.0–28.1) for the erlotinib arm and 28.1 months (95 %
CI, 0.0–66.2) for the GC arm (P = 0.201) (Fig. 2b, c).
Among patients receiving surgery, the median PFS was
8.6 months (95 % CI, 5.8–11.3) for the erlotinib armGC, gemcitabine/carboplatin; E, erlotinib. Note: The response rate of
.PFS and OS for the total population .PFS comparison between 2 arms
.OS comparison between the 2 arms . PFS for the resection patients




Fig. 2 PFS and OS. a PFS and OS for the total population; b PFS comparison between two arms; c OS comparison between two arms; d PFS for
the resection patients; e OS for the resection patients; f The 2nd PFS. Abbreviations: GC, gemcitabine/carboplatin; PFS, progression-free survival;
OS, overall survival
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(P = 0.018) and the median OS was 25.5 months and
57.3 months, respectively (P = 0.162) (Fig. 2d, e). The local
recurrence rate (5/12) was similar to the distant metastasis
rate (7/12) in the GC arm, whereas the common initial
failure model in the erlotinib arm was distant metastasis
(10/12), particularly brain metastases (3/10) and bilateral
lung metastases (8/10) (Additional file 1).
Treatment toxicity and feasibility
Overall, neoadjuvant therapies were well tolerated. The
most common side effects in the erlotinib arm were rash(100 %; 16.7 % as grade 3–4) and diarrhea (41.6 %). Only
one case had postoperative bleeding. Another case in the
erlotinib arm suffered from acute radiotherapy-induced
pneumonitis related to death. Three cases in the GC
arm exhibited grade 4 thrombocytopenia, two of which
received blood transfusion.
EGFR-TKI retreatment
The second median PFS, after the first progression, was
8.0 months (95 % CI, 4.0–12.0) for the erlotinib arm
and 4.0 months (95 % CI, 1.2–6.8) for the GC arm (P =
0.880) (Fig. 2f ). In addition, all six cases undergoing
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TKI retreatment at progression, with a median PFS of
9.4 months.
Biomarker
Genetic profiles in two arms are summarized in
Additional file 1, indicating rare genetic heterogeneity
between initial specimens and surgical samples after
neoadjuvant therapy. There was only one patient in each
arm whose gene mutation status transferred from mu-
tant type to wild type or contrariwise. The BIM deletion
polymorphism had no correlation with TKI efficacy
(Additional file 1). Immunohistochemistry (IHC) was
conducted to detect protein expressions on resected
samples after induced elotinib therapy. In all six cases,
pEGFR (Tyr1068) has been deregulated. Two cases with
L858R mutation enjoyed the longest PFS, among which
the p44/42MAPK (Erk1/2) (137 F5) was deregulated and
the pAkt (Thr308) (244 F9) was most activated com-
pared with other five cases. (Additional file 2).
Discussion
Several randomized controlled trials (RCTs) have estab-
lished the foundation of EGFR-TKI as first-line therapy in
advanced NSCLC with EGFR mutation [5–8]. Indications
for EGFR-TKIs have been transferred from second-line to
first-line in targeted populations. However, NSCLC is a
heterogeneous disease between early and advanced stages
and between wild and mutant EGFR lung cancer. There-
fore, principles for TKI therapy might be different
between first-line, neoadjuvant, and adjuvant treatment
[17]. The use of EGFR-TKI in neoadjuvant treatment ofTable 3 Comparison of neoadjuvant trials in lung cancer
Trial Phase TNM
Chemotherapy
Roth 1994 [21] II IIIA
Rosell 1994 [20] II IIIA
Scagliotti 2012 [19] (CHEST) III I-IIIA
TKI
Lara-Guerra 2009 [13] II I
II I
Schaake 2012 [14] II I-IIIA
II I-IIIA
Chemo-TKI
Lu 2013 [22] (CTONG 1101) II IIIA-N2
Bio-maker guided
Zhong 2014 (CSLC 0702) II IIIA-N2
II IIIA-N2
II IIIA-N2
CEP cyclophosphamide/etoposide/cisplatin, MIC mitomycin/ifosfamide/cisplatin, GC
RR response rate, EGFR epidermal growth factor receptor, Mut mutant, WT wild typeNSCLC has been evaluated in limited numbers of phase II
studies without survival data. Furthermore, customized
NSCLC adjuvant therapy (IFCT-0801, TASTE trial) [15]
and systematic therapy (BATTLE) [18] had validated its
feasibility. Thus, biomarker-guided neoadjuvant treatment
should be further evaluated in neoadjuvant settings for lo-
cally advanced but operable diseases.
To our knowledge, this is the first trial to evaluate
the feasibility of biomarker-guided neoadjuvant therapy
among patients with N2 NSCLC receiving TKI or
chemotherapy as neoadjuvant regimen based on EGFR
mutation status. The RR was 41.7 %, higher than 35.4 %
reported in Crystalloid Versus Hydroxyethyl Starch
Trial (CHEST) [19] with chemotherapy alone [20, 21],
5–11 % with TKI alone in phase II trial in the total
population [13, 14], and close to 46 % of the chemo-
TKI sequential treatment strategy in enriched popula-
tion [22] (Table 3). There were two cased achieving
downstaging of lymph nodes (2/6), while three of seven in
GC arm; and all of these five cases receiving complete re-
section. Besides, cases whose primary tumor responded to
neoadjuvant therapy had more chances of R0 surgeries, al-
though tumors might invade visceral pleura affecting
downstaging of T.
Overall, the PFS and OS were 7.9 and 23.2 months, re-
spectively, similar to the INT 0139 trial in radiotherapy
plus chemotherapy with/without surgical resection for
stage IIIA NSCLC [23]. Therefore, biomarker-guided
neoadjuvant treatment strategy in patients with IIIA-N2
NSCLC based on EGFR mutation status is feasible.
However, benefits for improved response to neoadju-
vant erlotinib therapy in this trial did not transfer toPopulation Regimen Sample RR
Total CEP 28 35 %
Total MIC 30 –
Total GC 129 35.4 %
Total G 36 11 %
Mut EGFR G 6 50 %
Total E 60 5 %
Enriched E 29 34 %
Enriched E + GC 39 46 %
Total E or GC 24 42 %
Mut EGFR E 12 58.3 %
WT-EGFR GC 12 25 %
gemcitabine/carboplatin, E erlotinib, G gefitinib, TKI tyrosine kinase inhibitor,
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most common failure model in the erlotinib arm was
distant metastasis (10/12). The PFS and OS did not dif-
fer significantly between two arms, although the PFS
and OS tended to be longer for all patients in the GC
arm. There appears to be no appropriate explanations for
why TKIs are not potentially contributable to better PFS
in the neoadjuvant setting but so dramatically better than
chemotherapy in patients with EGFR mutation in the
metastatic settings. In our study, an analysis of EGFR mu-
tation abundance in sequential plasma samples showed
that the abundance of plasma L858R dropped significantly
1 week after R0 resection, but it rebounded soon after
progression (Fig. 3). Furthermore, longer PFS contributed
partly to the expression of pEGFR and the downstream
molecules (Additional file 2). Riely and colleagues also re-
ported a rebound effect or disease flare phenomenon after
discontinuing TKI in patients with advanced EGFR mu-
tant NSCLC developing acquired resistance to TKI and
that the optimal treatment strategy should be to add an-
other agent to TKI or switch to systemic chemotherapeu-
tic drugs [24]. Similarly, after the termination of
neoadjuvant TKI before receiving surgery in patients with
IIIA-N2 disease, the sudden removal of oncogene inhib-
ition may promote potential residual circulating tumor
cells to accelerate and rebound, resulting in more aggres-
sive diseases. So it’s imperative to add standard care of
neoadjuvant chemotherapy to reduce disease flare and im-
prove complete resection rate of patients with IIIA-N2
NSCLC. Besides, this might partially explain why patients
in erlobinib relapsed and developed distant metastasis
with higher incidence. RADIANT study, a randomized
double-blind phase III trial of adjuvant erlotinib versusFig. 3 Plasma L858R abundance in the neoadjuvant TKI setting.
Abbreviations: PR, partial response; SD, stable disease; TKI, tyrosine
kinase inhibitor. One week after the R0 resection, the abundance of
plasma L858R decreased significantly, but it rebounded soon after
progression. However, the PR in the first- and second-line TKI therapy
did not decrease the level of plasma L858R for one caseplacebo following complete tumor resection with/without
adjuvant chemotherapy in patients with stage IB-IIIA
EGFR positive (IHC/FISH) non-small cell lung, reported
in ASCO (American Society of Clinical Oncology, 2014)
by Karen Kelly and colleagues, figured out that more pa-
tients developed brain relapse in erlotinib group than in
placebo group (40.0 % vs. 12.9 %, respectively) and that no
statistically significant difference of survival benefits were
observed, indicating that TKIs just delay tumor recurrence
rather than eliminate chances of recurrence and that poor
ability of TKI permeating through blood–brain barrier re-
sults in relative lower concentration of erlotinib in central
nervous system. Another recently activated trial, the AL-
CHEMIST study (registered on ClinicalTrials.gov as
NCT02194738), aimed at comparing erlotinib and placebo
as adjuvant therapy based on genetic testing. Although
this study detects EGFR mutation status by direct sequen-
cing which is with less sensitivity, its results indeed de-
serve expectation to improve tailored treatment in real
world. Thus, it is warranted to combine neoadjuvant and
adjuvant TKI treatment and enhance longer duration of
TKI and strength of systemic chemotherapy as standard
care when diseases relapse based on genetic analysis [25].
In our study, there was one patient receiving surgical re-
section in each arm whose genetic mutation status trans-
ferred from mutant type to wild type or contrariwise
(Additional file 1). Chin et al. [26] figured out that first-
line chemotherapy to patients with EGFR mutant NSCLC
would decrease sensitivity to TKIs as second-line therapy.
Similar work conducted by Wang J [27] indicated that
intra-tumoral heterogeneity may be contributable to re-
duced EGFRmutation frequency caused by chemotherapy.
According to Zhou Q [28], EGFR mutation abundance is
significantly related to identity of mutation status and
sensitivity of detecting methods. Gene mutation switch-
ing to EGFR wild type in erlotinib arm after neoadju-
vant TKI therapy is possibly due to relative low
abundance of EGFR mutation. Therefore, detecting
methods with more sensitivity are extremely essential
to identify pseudo-heterogeneity. Direct sequencing
(DS) could detect samples with more than 10 % EGFR
mutation frequency, whereas ARMS is with higher sen-
sitivity (0.1–1 %) [29]. However, DS was most widely
used when our study was designed and activated; low-
ing EGFR mutation abundance might not be detected
and potential bias could cloudy the interpretation of
current data. That is why there is an ongoing study in
our team to compare efficacy and accuracy of DS vs.
ARMS.
Several limitations existed in our study. Firstly, accord-
ing to clinical characteristics in Table 1, smoking dur-
ation in erlotinib arm was apparently shorter than that
in GC arm despite of P > 0.05. However, EGFR mutant
NSCLC is indeed different from EGFR wild type NSCLC
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sides, more genetic heterogeneity of EGFR mutation was
observed in erlotinib, which might result in relative
lower response rate of TKI and cloudy interpretation of
data in our study. Our study were based on populations
with different biological features, with EGFR mutant and
wild type, which is the basic principle of biomarker-
guided study design. Although biases related to non-
randomized clinical trials existed, our trial contributed to
neoadjuvant TKI and biomarker-guided therapy in pa-
tients with IIIA-N2 NSCLC. Furthermore, based on this
trial, CTONG has launched a multicenter RCT to eluci-
date the role of perioperative TKIs [CTONG1103, a na-
tional, multicenter, randomized, controlled, open-label,
phase II trial of erlotinib versus GC as (neo)adjuvant ther-
apy in stage IIIA-N2 NSCLC with EGFR mutation in exon
19 or 21 (EMERGING); registered in ClinicalTrials.gov
(NCT01407822)] in 2011. Ninety patients with resectable
stage IIIA-N2 NSCLC harboring EGFR mutations will be
randomized to neoadjuvant erlotinib arm for 42 days or
GC arm for two cycles. After complete resections, patients
will continue erlotinib for 1 year or the GC regimen for
two cycles (Fig. 4).
Conclusions
To our knowledge, CSLC 0702 is the first phase II study of
biomarker-guided neoadjuvant treatment strategy for IIIA-
N2 NSCLC based on EGFR mutation status with PFS and
OS data. The trial met its primary outcome and validated
the feasibility of this strategy. Nevertheless, erlotinib alone
in neoadjuvant setting tended to show an improved re-
sponse but without better PFS or OS. Brain and lung me-
tastases were most common failure models. The role of
TKIs in first-line setting of advanced NSCLC should not
be simply extrapolated to neoadjuvant therapy. More RCTsFig. 4 Study design of the CTONG 1103 (EMERGING). Abbreviations:
NSCLC, non-small cell lung cancer; EBUS, endobronchial ultrasound;
EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative
Oncology Group; PD, progressive disease; ORR, object response rate,
CR, complete response; PFS, progression-free survival; OS, overall
survival; QOL, quality of lifecombining neoadjuvant with adjuvant EGFR-TKI therapy
in a larger population are warranted to validate the role of
perioperative TKI therapy. We look forward to results of
these trials to provide convincing evidences for customized
therapy for patients with resectable NSCLC [30].
Methods
Study design
This study, conducted in Guangdong General Hospital,
China, was designed as an open-label, single-center,
non-randomized, phase II clinical trial. It was approved
by a local independent ethics committee and designed in
accordance with Good Clinical Practice Guidelines.
Written informed consents were obtained from patients
before the start of treatment. Patients with resectable
stage IIIA-N2 NSCLC diagnosed by mediastinoscopy or
EBUS were assigned at a ratio of 1:1 to the neoadjuvant
erlotinib arm or the GC arm based on EGFR mutation
status. This study was sponsored by Chinese Society of
Lung Cancer (CSLC 0702), the predecessor of Chinese
Thoracic Oncology Group (CTONG), and was registered
at ClinicalTrials.gov as NCT00600587.
Based on detection of mutation status, patients with
mutant type EGFR in tumor tissue received 42-day ad-
ministration of neoadjuvant erlotinib, and patients with
wild type EGFR received an intended three cycles of GC
regimen to serve as concurrent assignment. A CT scan
or a positron emission tomography/computed tomog-
raphy (PET/CT) was performed at 1–7 days after neoad-
juvant treatment discontinuation. Patients with stable
disease (SD) or a partial response (PR) underwent a
thoracotomy which was scheduled to be done within
1 week after discontinuation. A radical resection of the
tumor preferably by lobectomy and regional lymph node
dissection with sampling of at least three N1 and three
mediastinal lymph node stations was involved. Patients
with progressive disease received second-line therapy or
combined chemoradiotherapy. The primary outcome
was response to neoadjuvant therapy. Secondary out-
come measures were safety, PFS, and OS (Fig. 5).
Patient eligibility
Patients with newly diagnosed resectable stage IIIA-N2
NSCLC and confirmed by mediastinoscopy or EBUS (i.e.,
clinical T1-3 N2) were enrolled. All patients were evaluated
in a multidisciplinary tumor board discussion. The diagno-
sis had to be histologically or cytologically confirmed with
sufficient tissue samples to perform gene analysis. Candi-
dates, having ECOG performance status of 0–1, adequate
hematological and hepatic-renal functions, and quali-
fied lung function, were required to tolerate neoadju-
vant therapy and a lobectomy and radical lymph node
dissection. No pregnant or breast feeding patients were
included. In addition, patients with a small cell lung
Fig. 5 Flow chart. Abbreviations: NSCLC, non-small cell lung cancer;
EGFR, epidermal growth factor receptor; E, erlotinib; GC, gemcitabine/
carboplatin; PR, partial response; SD, stable disease; PD, progressive
disease; NA, not available; PORT: postoperative radiotherapy; Nad,
neoadjuvant; MT, mutant type; WT, wild type
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exposure to investigational drug therapy or other con-
current anticancer therapies outside of this trial were
excluded.
Efficacy assessment
Tumor specimens and imaging data were reviewed and
analyzed by the Guangdong Lung Cancer Institute. The
CT or FDG-PET/CT scans were performed after study
treatments were compared with baseline scans. Radio-
logical tumor response after neoadjuvant therapy was
assessed according to the Response Evaluation Criteria
in Solid Tumors measurement criteria, version 1.1.
Molecular analyses
DNA was extracted from formalin-fixed paraffin-
embedded (FFPE) samples or frozen resection samples
with macroscopically viable tumor tissue. Mutation
testing was performed at the certified laboratory of
Guangdong Lung Cancer Institute. EGFR and KRAS
mutations in the initial biopsy, postoperative material,
and recurrent tumor tissue were determined by Sanger
sequencing, and EGFR mutations in plasma were tested
using ARMS according to the protocol of the DxS
EGFR mutation test kit (DxS). EML4-ALK translocation
was analyzed by FISH using Vysis ALK Break Apart
FISH Probe Kit according to the manufacturer’s in-
struction. In addition, the deletion polymorphism of
the Bcl-2-interacting mediator of cell death (BIM) gene
in intron 2 was retrospectively examined by Sanger se-
quencing to validate its predictive role for TKI efficacy.
IHC was conducted to detect the protein expressions of
mutant EGFR and downstream molecules using rabbitmAbs from Cell Signaling Technology according to the
protocols recommended by the manufacturer [31, 32].
Statistical analysis
Power analysis of one proportion non-inferiority was ap-
plied to provide 95 % power to declare the treatment
sufficiently active for a response rate ≥42.5 % (the aver-
age of 50 % of TKI in EGFR mutant lung cancer and
35 % of GC regimen in neoadjuvant setting) in the
biomarker-guided neoadjuvant treatment strategy and
11 % for the history reference of neoadjuvant TKI ther-
apy [13, 19]. A sample size of 22 achieves 96 % power to
detect a difference of −0.01 using a one-sided binomial
test. The target significance level is 0.05. The actual sig-
nificance level achieved is 0.0344. These results assume
a baseline proportion of 0.12 and that the actual propor-
tion is 0.417 [33].
Response rates were analyzed by use of the Fisher’s
Exact Test. Survival was estimated with Kaplan-Meier
methodology and was summarized as a median value
with range and a two-sided 95 % CI. A Cox proportional
hazards model was utilized to estimate hazard ratios
(HR) and 95 % CI. SPSS version 21 was used for statis-
tical analyses. All analyses were exploratory only.
Additional files
Additional file 1: Comparison of gene mutation status and tumor
staging before and after neoadjuvant therapy and corresponding
disease failure model. Abbreviations: EGFR, epidermal growth factor
receptor; LN, lymph node; GC, gemcitabine/carboplatin; PFS, progression-free
survival; RT, radiotherapy; PORT, postoperative radiotherapy; RR, response rate;
PR, partial response; SD, stable disease; PD, progressive disease; NA, not
available; WT, wild type; BIM, BCL2L11; cT staging: primary staging of tumor
before neoadjuvant therapy; cN staging: primary staging of lymph nodes
before neoadjuvant therapy; pT staging: restaging of tumor based on
pathological results of surgical resection; pN staging: re-staging of lymph
nodes based on pathological results of surgical resection. (LOG 0 bytes).
Additional file 2: Immunohistochemistry for mutant EGFR and
downstream molecules on the resected samples after induction
erlotinib. Abbreviations: EGFR, epidermal growth factor receptor; PFS,
progression-free survival. Note: All six cases in the erlotinib arm that
underwent resection gained partial response to tyrosine kinase inhibitor.
Immunohistochemistry was conducted to detect the protein expressions
on the resected samples after induction elotinib. In all the 6 cases, pEGFR
(Tyr1068) has been deregulated. Cases 2 with L858R mutation enjoyed
the longest PFS of 23 months, among which the p44/42MAPK (Erk1/2)
(137 F5) was deregulated and the pAkt (Thr308) (244 F9) was most
activated compared with other 5 cases.
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